Latham, A&O Shearman Among Firms Advising on Landmark $8B EU Biotech Deal
A&O Shearman, Latham & Watkins, NautaDutilh, and Kromann Reumert are advising Genmab on its €6.8 billion ($8 billion) all-cash acquisition of Merus. This deal highlights the growing consolidation in the EU life sciences sector and is one of the largest biotech transactions in Europe to date.